Trial reportThe Journal of clinical psychiatry2013
Treatment response, symptom remission, and wellness in obsessive-compulsive disorder.
Trial report in The Journal of clinical psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 91 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CBT Augmentation for SRI Pharmacotherapy in OCD
Cognitive Behavioral Therapy Plus Motivational Interviewing for Obsessive Compulsive Disorder
Maximizing Treatment Outcome in OCD
Who cites it
91 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Deep brain stimulation for obsessive-compulsive-disorder: a systematic review and meta-analysis of individual participant outcome data from sham-controlled trials.Molecular psychiatry · 2025Pooled it
- Functional connectivity alterations between default mode network and occipital cortex in patients with obsessive-compulsive disorder (OCD).NeuroImage. Clinical · 2022Pooled it
- Homework adherence in exposure-based CBT for youth with obsessive-compulsive disorder: Clinical outcomes and predictors across treatment.Behaviour research and therapy · 2026Trial
- Virtual Exposure With Response Prevention for Obsessive-Compulsive Disorder: Randomized Controlled Trial.Journal of medical Internet research · 2026Trial
- Predictors of clinical worsening during a discontinuation trial of serotonin reuptake inhibitors for obsessive compulsive disorder.Journal of anxiety disorders · 2024Trial
- Resting-State Connectivity and Response to Psychotherapy Treatment in Adolescents and Adults With OCD: A Randomized Clinical Trial.The American journal of psychiatry · 2023Trial
- Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.JAMA psychiatry · 2022Trial
- Behavioral Therapy Teams for Obsessive-Compulsive Disorder: Lessons Learned From a Pilot Randomized Trial in a Community Mental Health Center.Behavior therapy · 2021Trial
- Therapist-Assisted Internet-Based Cognitive Behavioral Therapy Versus Progressive Relaxation in Obsessive-Compulsive Disorder: Randomized Controlled Trial.Journal of medical Internet research · 2018Trial
- Acceptability, Feasibility, and Effectiveness of Internet-Based Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder in New York.Behavior therapy · 2018Trial
- Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.JCI insight · 2018Trial
- Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder.Depression and anxiety · 2018Trial
- A pilot randomized controlled trial of aerobic exercise as an adjunct to OCD treatment.General hospital psychiatry · 2017Trial
- The effect of treatment on quality of life and functioning in OCD.Comprehensive psychiatry · 2017Trial
- Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes well?Behaviour research and therapy · 2016Trial
- Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.JAMA psychiatry · 2016Trial
- Cognitive Mediation of Symptom Change in Exposure and Response Prevention for Obsessive-Compulsive Disorder.Behavior therapy · 2016Trial
- Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.Psychotherapy and psychosomatics · 2016Trial
- Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.The Journal of clinical psychiatry · 2015Trial
- Refining Clinical Judgment of Treatment Response and Symptom Remission Identification in Childhood Anxiety Using a Signal Detection Analysis on the Pediatric Anxiety Rating Scale.Journal of child and adolescent psychopharmacology · 2015Trial
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundObsessive-compulsive disorder (OCD) is defined both by intrusive, unwanted thoughts, images, or impulses and by repetitive behavioral or mental acts that are often performed to try to alleviate anxiety. The ultimate goal of treatment for OCD is to reduce the symptoms as well as help patients achieve "wellness." Currently, however, there are no widely accepted, empirically supported criteria for determining wellness in OCD.
methodBuilding on previous research, the current study examined the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score that most reliably identified patients who responded to treatment, those who achieved symptom remission, and those who achieved wellness. The current study pooled data from 4 randomized controlled OCD treatment trials (N = 288), which took place between 1990 and 2011 at 2 academic sites. Participants (mean age = 36.8 years) had a primary diagnosis of DSM-IV-TR OCD (mean Y-BOCS score = 25.9).
resultsSignal detection analyses showed that a pretreatment-to-posttreatment reduction of ≥ 35% on the Y-BOCS was most predictive of treatment response as defined by the Clinical Global Impressions (CGI)-Improvement scale. A posttreatment Y-BOCS score of ≤ 14 was the best predictor of symptom remission, whereas a score of ≤ 12 was the best predictor of wellness, as defined by symptom remission (defined by the CGI-Severity scale), good quality of life (as measured by the Quality of Life Enjoyment and Satisfaction Questionnaire), and a high level of adaptive functioning (as assessed by the Social Adjustment Scale-Self-Report). Because efficiency (0.86) and specificity (0.88) were highest at the cutoff of ≤ 12, this cutoff score was determined to be the best indicator of wellness.
conclusionsThe present findings support the convergent validity of the Y-BOCS with other measures of well-being (quality of life, adaptive functioning) and highlight the utility of a Y-BOCS score ≤ 12 as a solo indicator of wellness in outcome studies. The use of empirically supported criteria for defining wellness in OCD is recommended to facilitate comparisons across treatment outcome studies and to inform clinical treatment planning.
trial registrationPooled data analyzed in this study were from 4 clinical trials, 3 of which are registered at ClinicalTrials.gov (identifiers: NCT00045903, NCT00389493, NCT00316316).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.